Moderna pitches virus vaccine at around $50-$60 per course -FT

Pfizer, Moderna and Merck & Co have said they plan to sell their vaccines at a profit, while some drugmakers, including Johnson & Johnson have announced plans to price their vaccines on a not-for-profit basis.

Moderna Inc is planning to price its coronavirus vaccine at $50 to $60 per course - higher than other vaccine makers have agreed to charge governments, the Financial Times reported on Tuesday, citing sources familiar with the matter.

The price would apply to the United States and other high-income countries, according to the report https://on.ft.com/334eV4g. A Moderna spokesperson said the company was in discussions with governments about potential supply of mRNA-1273, but did not give any details on pricing "given the confidential nature of the discussions and contracts".

Moderna's proposed price of $50 to $60 for a course, or $25 to $30 per dose, is higher than that pitched by Pfizer Inc and its German partner BioNTech in a $2 billion deal with the U.S. government at $39 for a course, or $19.50 per dose. Pfizer, Moderna and Merck & Co have said they plan to sell their vaccines at a profit, while some drugmakers, including Johnson & Johnson have announced plans to price their vaccines on a not-for-profit basis.